Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Assets (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Other Non-Current Assets for 9 consecutive years, with $25.9 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 4.84% to $25.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.9 million through Dec 2025, up 4.84% year-over-year, with the annual reading at $25.9 million for FY2025, 4.84% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $25.9 million at Denali Therapeutics, up from $25.1 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $50.6 million in Q2 2024, with the low at $3.6 million in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $19.3 million, with a median of $15.7 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets soared 382.17% in 2021, then tumbled 54.58% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $11.9 million in 2021, then grew by 12.87% to $13.4 million in 2022, then skyrocketed by 35.41% to $18.1 million in 2023, then soared by 36.37% to $24.7 million in 2024, then rose by 4.84% to $25.9 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $25.9 million, $25.1 million, and $23.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.